Allurion Technologies (ALUR) Competitors $2.05 +0.02 (+0.99%) Closing price 03:59 PM EasternExtended Trading$2.06 +0.01 (+0.68%) As of 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALUR vs. PSTV, CTSO, DXR, SURG, TELA, MDAI, PYPD, TMDIF, SRTS, and APTShould you be buying Allurion Technologies stock or one of its competitors? The main competitors of Allurion Technologies include Plus Therapeutics (PSTV), Cytosorbents (CTSO), Daxor (DXR), SurgePays (SURG), TELA Bio (TELA), Spectral AI (MDAI), PolyPid (PYPD), Titan Medical (TMDIF), Sensus Healthcare (SRTS), and Alpha Pro Tech (APT). These companies are all part of the "medical equipment" industry. Allurion Technologies vs. Its Competitors Plus Therapeutics Cytosorbents Daxor SurgePays TELA Bio Spectral AI PolyPid Titan Medical Sensus Healthcare Alpha Pro Tech Allurion Technologies (NYSE:ALUR) and Plus Therapeutics (NASDAQ:PSTV) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings. Is ALUR or PSTV more profitable? Allurion Technologies has a net margin of -158.30% compared to Plus Therapeutics' net margin of -357.85%. Company Net Margins Return on Equity Return on Assets Allurion Technologies-158.30% N/A -59.91% Plus Therapeutics -357.85%N/A -117.72% Do analysts prefer ALUR or PSTV? Allurion Technologies presently has a consensus price target of $9.25, indicating a potential upside of 351.22%. Plus Therapeutics has a consensus price target of $8.00, indicating a potential upside of 799.38%. Given Plus Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Plus Therapeutics is more favorable than Allurion Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Allurion Technologies 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Plus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.83 Which has better valuation & earnings, ALUR or PSTV? Allurion Technologies has higher revenue and earnings than Plus Therapeutics. Plus Therapeutics is trading at a lower price-to-earnings ratio than Allurion Technologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAllurion Technologies$32.11M0.50-$7.20M-$12.53-0.16Plus Therapeutics$5.82M15.17-$12.98M-$2.24-0.40 Does the media refer more to ALUR or PSTV? In the previous week, Plus Therapeutics had 2 more articles in the media than Allurion Technologies. MarketBeat recorded 3 mentions for Plus Therapeutics and 1 mentions for Allurion Technologies. Plus Therapeutics' average media sentiment score of 0.71 beat Allurion Technologies' score of 0.00 indicating that Plus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allurion Technologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Plus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals believe in ALUR or PSTV? 21.4% of Allurion Technologies shares are owned by institutional investors. Comparatively, 3.3% of Plus Therapeutics shares are owned by institutional investors. 9.6% of Allurion Technologies shares are owned by company insiders. Comparatively, 0.8% of Plus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has more risk and volatility, ALUR or PSTV? Allurion Technologies has a beta of -0.45, meaning that its share price is 145% less volatile than the S&P 500. Comparatively, Plus Therapeutics has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500. SummaryPlus Therapeutics beats Allurion Technologies on 9 of the 16 factors compared between the two stocks. Get Allurion Technologies News Delivered to You Automatically Sign up to receive the latest news and ratings for ALUR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALUR vs. The Competition Export to ExcelMetricAllurion TechnologiesMED PRODUCTS IndustryMedical SectorNYSE ExchangeMarket Cap$15.76M$10.98B$6.16B$22.13BDividend YieldN/A1.83%5.50%3.55%P/E Ratio-0.1622.2285.5829.95Price / Sales0.5028.76612.7472.75Price / CashN/A25.6126.3018.33Price / Book-0.073.4812.874.65Net Income-$7.20M$210.63M$3.30B$1.01B7 Day Performance5.13%2.52%4.80%1.21%1 Month Performance-6.95%2.31%8.11%3.21%1 Year Performance-88.37%-6.64%75.85%14.02% Allurion Technologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALURAllurion Technologies1.4066 of 5 stars$2.05+1.0%$9.25+351.2%-88.5%$15.76M$32.11M-0.16501PSTVPlus Therapeutics3.8505 of 5 stars$0.83+34.7%$7.88+847.5%-43.8%$61.26M$5.82M-0.3720Analyst ForecastGap UpHigh Trading VolumeCTSOCytosorbents1.4057 of 5 stars$0.93-0.9%$5.50+494.3%-17.3%$58.60M$36.11M-5.44220Gap DownDXRDaxor3.851 of 5 stars$12.96+7.6%$25.00+92.9%+61.5%$58.28MN/A0.0037Short Interest ↓Gap DownHigh Trading VolumeSURGSurgePays3.3575 of 5 stars$2.86+0.4%$9.00+214.7%+52.2%$58.23M$36.46M-1.1540Analyst ForecastTELATELA Bio1.9715 of 5 stars$1.50+3.4%$4.50+200.0%-42.2%$57.44M$69.30M-1.34120MDAISpectral AI2.4925 of 5 stars$2.15+2.4%$3.50+62.8%+116.5%$56M$29.58M-3.1283Positive NewsGap UpPYPDPolyPid2.8418 of 5 stars$3.33-0.3%$12.40+272.4%-2.4%$53.02MN/A-0.8780Short Interest ↑TMDIFTitan MedicalN/A$0.45+6.0%N/A+1,226.1%$51.32M$17.63M-0.3650Gap UpSRTSSensus Healthcare2.4763 of 5 stars$3.17+2.3%$8.00+152.4%-45.5%$50.96M$41.81M-52.8340APTAlpha Pro Tech2.7455 of 5 stars$4.81-1.2%N/A-15.3%$50.38M$58.56M13.00120News CoverageShort Interest ↓ Related Companies and Tools Related Companies Plus Therapeutics Competitors Cytosorbents Competitors Daxor Competitors SurgePays Competitors TELA Bio Competitors Spectral AI Competitors PolyPid Competitors Titan Medical Competitors Sensus Healthcare Competitors Alpha Pro Tech Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ALUR) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredIs This Warren’s Buffett’s #1 AI Investment?Did you know that Warren Buffett is investing in what Jeff Brown believes will be the next generation of artif...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredWarren Buffett’s #1 AI Stock is Not Even on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he...Banyan Hill Publishing | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredExpert Alert: Massive Bubble Could Crash Your WealthOn July 4th, Trump signed the “One Big Beautiful Bill,” adding $3.4 trillion to the national debt — and pushin...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allurion Technologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allurion Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
